20 citations,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
3 citations,
January 2015 in “Journal of drug assessment” Taking five small dutasteride capsules is the same as taking one larger capsule.
78 citations,
August 2012 in “Human molecular genetics online/Human molecular genetics” A new gene, JMJD1C, may affect testosterone levels in men.
70 citations,
March 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
48 citations,
September 2013 in “Oncologist” Endocrine therapies for cancer significantly increase the risk of hair loss.
44 citations,
June 2015 in “PubMed” Finasteride for hair loss may cause long-lasting side effects like impotence and low libido, but trials lack proper safety reporting.
31 citations,
June 2015 in “British Journal of Dermatology” Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
13 citations,
December 2017 in “Archives of Medical Sciences” Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.
The new treatment regimen was effective in promoting significant hair growth in all 15 male patients with androgenic alopecia.
March 2024 in “Research Square (Research Square)” Scalp cooling therapy helps preserve hair during chemotherapy for most patients.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
June 2013 in “Annals of the rheumatic diseases” Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
September 2015 in “Korean Journal of Clinical Pharmacy” Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
31 citations,
October 2015 in “BJUI” Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
33 citations,
October 2013 in “Journal of The American Academy of Dermatology” Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
17 citations,
February 2013 in “Australasian Journal of Dermatology” Finasteride and low-dose dutasteride combo improves hair growth and reduces hair loss with no major side effects.
December 2023 in “International journal of research in dermatology” Adding PRP to topical mometasone improves and speeds up alopecia areata treatment.
36 citations,
June 2017 in “Journal of Cutaneous Medicine and Surgery” The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.
20 citations,
February 2017 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
1 citations,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
January 2019 in “Egyptian Journal of Dermatology and Venereology /Egyptian Journal of Dermatology and Venerology” Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.
20 citations,
May 2022 in “British Journal of Dermatology” People with alopecia areata have a higher risk of depression and anxiety, and often face unemployment and work absences.
10 citations,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata greatly affects people's life quality, mental health, and work life.
6 citations,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
3 citations,
June 2023 in “Journal of dermatological treatment” Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
1 citations,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.